Enalees launches new Rhéa® respiratory panel: a new clinical reference for LAMP PCR diagnosis of respiratory diseases in livestock
Enalees, a French company pioneering molecular veterinary diagnostics, announces the launch of its new respiratory panel, expanding the Rhéa® range, designed for cattle, sheep, and goats. Based on LAMP technology (Loop-mediated Isothermal Amplification), this panel can identify in under 30 minutes the main pathogens responsible for respiratory diseases in ruminants: BRSV (Bovine Respiratory Syncytial Virus), Mycoplasma bovis, Pasteurella multocida, and BHV-4 (Bovine Herpesvirus 4).
With this innovation, Enalees offers veterinarians a simple and rapid point-of-care diagnostic solution, designed to improve animal welfare, strengthen herd health management, and optimise the economic efficiency of farms.
fast and reliable tool, built for the field
Unlike conventional PCR, LAMP technology operates at a constant temperature, significantly reducing analysis time while maintaining comparable sensitivity. The new Rhéa® respiratory panel is used with a portable reader, requiring neither a laboratory nor expensive heavy equipment, and provides actionable results directly in the clinic or on-farm.
The ability to analyse a sample at the animal’s side allows immediate decision-making: biosecurity measures such as isolation, and targeted, personalised treatment.
Laurent Thiery, CEO of Enalees:
« With this new panel in the Rhéa® range, we provide veterinarians with a field-ready solution that can transform the management of respiratory diseases. Results in just 30 minutes, directly in the clinic, become a genuine lever to improve animal welfare, reduce economic losses, and enhance herd health management »
A major economic challenge: acting early to limit losses
Respiratory diseases are among the leading causes of economic losses in livestock: mortality, slower average daily gain (ADG), reduced milk production, repeated treatments, and prolonged recovery.
By enabling early diagnosis, the Rhéa® respiratory panel helps to:
- Reduce growth losses (ADG)
- Lower veterinary costs through more targeted treatments
- Limit pathogen spread within the herd
- Reduce antibiotic use when the cause is viral
Strengthening the veterinarian’s role in responsible practice
Immediate results give veterinarians greater accuracy, responsiveness, and advisory capacity. A positive test for a viral agent such as BRSV can prevent unnecessary antibiotic treatment when the animal carries only that pathogen. The Rhéa® Respiratory panel also detects co-infections more broadly, allowing the administration of appropriate treatment. This rational diagnostic approach aligns with national objectives to reduce antimicrobial resistance and supports a modern vision of animal health.
[Focus UK]
Since May 2024, the new UK Veterinary Medicines Regulations prohibit the routine use of antibiotics in livestock and only allow group prophylaxis under very limited circumstances (saveourantibiotics.org). In this post-Brexit context, the UK cattle sector is seeking to maximise productivity with more intensive herds while maintaining strict health standards. The UK estimates losses due to respiratory diseases at around £80 million per year (nadis.org.uk).
Rhéa® supports UK veterinary practices by complementing the RCVS “Test–Treat–Evaluate” approach: veterinarians can perform tests on-farm without waiting for laboratory results. This enhances their role as herd health consultants, ensuring rapid compliance with new regulatory requirements (hygiene, targeted vaccination). The panel fits into UK farm health programmes, helping improve herd competitiveness amid rising costs and commercial pressures (export under “Red Tractor” standards).
About d’Enalees
Enalees develops, manufactures and markets rapid isothermal PCR tests that enable veterinarians to diagnose suspected infectious diseases – either in the clinic or directly in the field – without the need to send samples to a specialized laboratory. Its team, mainly made up of doctors, veterinarians and biology engineers and technicians, develops innovative tests for both pets and livestock.
The tests use LAMP technology. This allows the amplification of the DNA sequence and offers four advantages: specificity and a sensitivity equivalent to PCR, while combining rapid results with robustness.
Enalees offers more than 60 tests via three ranges: Epona® (horses), Astéria® (dogs/cats) and Rhéa® (ruminants). These can detect more than 25 infectious diseases, including rhinopneumonitis, flu, borreliosis (the pathogen that causes Lyme disease), even leptospirosis.
The Enalees facilities (R&D and production) have been at the Genopole Biocluster in Essonne, France since 2016. Enalees has a production capacity of one million units per year, serving its own animal health business and its partners, for whom it develops and manufactures custom tests.
Enalees currently has 43 employees globally.
Contact Enalees
Florence Fombertasse
Marketing & Communication CO
florence.fombertasse@enalees.com
+33 (0)749 329 506